SynthesisFrontiers in oncology2024
Predictive value of
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- The potential of MRI radiomics based on extrapulmonary metastases in predicting EGFR mutations: a systematic review and meta-analysis.Biomedical engineering online · 2025Pooled it
- Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics.BMC medical imaging · 2025Article
- Interpretable machine learning model integrating CT radiomics, CTR, and clinical features for EGFR mutation prediction in ≤3 cm lung adenocarcinoma nodules.Annals of medicine · 2025Article
- Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration.Medical oncology (Northwood, London, England) · 2025Review
- Predictive classification of lung cancer pathological based on PET/CT radiomics.Japanese journal of radiology · 2025Article
- The influence of image selection and segmentation on the extraction of lung cancer imaging radiomics features using 3D-Slicer software.BMC cancer · 2025Article
- Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer.Journal of applied clinical medical physics · 2025Article
- Prediction of EGFR mutations in non-small cell lung cancer: a nomogram based onFrontiers in oncology · 2025Article
- Does FDG PET-Based Radiomics Have an Added Value for Prediction of Overall Survival in Non-Small Cell Lung Cancer?Journal of clinical medicine · 2024Article
- Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the value of Methods: The PubMed, Embase, Cochrane Library, Web of Science, and CNKI databases were searched from the earliest available date to June 30, 2023. The meta-analysis was performed using the Stata 15.0 software. The methodological quality and risk of bias of included studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and Radiomics Quality Score criteria. The possible causes of heterogeneity were analyzed by meta-regression. Results: A total of 17 studies involving 3763 non-small cell lung cancer patients were finally included. We analyzed 17 training cohorts and 10 validation cohorts independently. Within the training cohort, the application of Conclusion: Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022385364.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.